21 Amendments of Biljana BORZAN related to 2019/2816(RSP)
Amendment 1 #
Citation 1 a (new)
- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union, on the polluter pays principle, the precautionary principle and control at source principle,
Amendment 16 #
Citation 12 a (new)
- having regard to the Commission Communication of the 11 December 2019 entitled “European Green Deal” (COM(2019)640),
Amendment 22 #
Citation 12 b (new)
- having regard to its resolution of 15 January 2020 on the European Green Deal (2019/2956(RSP)),
Amendment 24 #
Citation 21 a (new)
- having regard to the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation (EC) No 1907/2006,
Amendment 30 #
Citation 23 a (new)
- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,
Amendment 62 #
Recital G
G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment, such as the impact on drinking water sources;
Amendment 67 #
Recital L
Amendment 83 #
Paragraph 5
5. Considers that a holistic approach is needed to tackle pharmaceutical pollution at source, taking into account the entire life cycle of drugs; notes with concern the role that pharmaceuticals play in contributing to antimicrobial resistance when released into the environment via the discharge of animal manure, water pollution or improper disposal; stresses that regulatory actions have to be taken in line with the precautionary principle and the control at source principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;
Amendment 97 #
Paragraph 7
7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plantswastewater treatment plants currently cannot effectively filter out all pharmaceutical products, due to the intrinsically different chemical properties of the relevant substance;
Amendment 104 #
Paragraph 8
8. Notes that due to generally low concentrations, risks for human health are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of many pharmaceuticals ending up in the environment;
Amendment 115 #
Paragraph 10
10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants, in accordance with the control at source principle, and additional hot spots such as certain wastewater treatment plants;
Amendment 127 #
Paragraph 11
11. Calls on the Commission to facilitate the exchange of existing best practices and to take clear legislative action on tackling pharmaceuticals in the environment, both as a result of the manufacturing process and of the use and disposal of pharmaceuticals;
Amendment 162 #
Paragraph 16
16. Considers that the environmental impacts of pharmaceuticals couldshall be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; Metabolites, degradation products and cocktail effects of pharmaceutical substances shall also be considered therein;
Amendment 179 #
Paragraph 20
20. Points to the important role of procurement policy in promoting greener pharmaceuticals in design and manufacturing; calls on the Commission to develop clear guidance on this issue;
Amendment 181 #
Paragraph 21 a (new)
21 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give EU inspectors the ability to control manufacturing discharges at overseas pharmaceutical factories supplying the EU market;
Amendment 212 #
Paragraph 28 a (new)
28 a. Emphasises that the affordability of water has to be maintained and costly treatment plant upgrades should not be shifted to consumers; therefore takes the view that financing depollution via wastewater charges would only burden citizens and would not provide any incentive to reduce the input of pollutants during the manufacturing procedure;
Amendment 216 #
Paragraph 29
29. Considers that pharmaceutical production plants should pre-treat their wastewater, applying Best Available Techniques;
Amendment 225 #
Paragraph 30
30. Calls for full enforcement of the existingon Member States to set up and enforce provisions with regard to take- back schemes for unused medicines;
Amendment 240 #
Paragraph 33 a (new)
33 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards (EQS) Directive;
Amendment 247 #
Paragraph 35
35. Emphasises the need to support further research, particularly under the next multi-annual financial framework, on the direct impact on human health and ecology of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment;
Amendment 253 #
Paragraph 37
37. Recalls that pharmaceutical environmental information such as the impact on water, environmental behaviour, degradability and possible cocktail effects plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;